Original Article
Early Antiretroviral Therapy and Mortality among HIV-Infected Infants
N Engl J Med 2008; 359:2233-2244November 20, 2008
- Abstract
Background
In countries with a high seroprevalence of human immunodeficiency virus type 1 (HIV-1), HIV infection contributes significantly to infant mortality. We investigated antiretroviral-treatment strategies in the Children with HIV Early Antiretroviral Therapy (CHER) trial.
Methods
HIV-infected infants 6 to 12 weeks of age with a CD4 lymphocyte percentage (the CD4 percentage) of 25% or more were randomly assigned to receive antiretroviral therapy (lopinavir–ritonavir, zidovudine, and lamivudine) when the CD4 percentage decreased to less than 20% (or 25% if the child was younger than 1 year) or clinical criteria were met (the deferred antiretroviral-therapy group) or to immediate initiation of limited antiretroviral therapy until 1 year of age or 2 years of age (the early antiretroviral-therapy groups). We report the early outcomes for infants who received deferred antiretroviral therapy as compared with early antiretroviral therapy.
Results
At a median age of 7.4 weeks (interquartile range, 6.6 to 8.9) and a CD4 percentage of 35.2% (interquartile range, 29.1 to 41.2), 125 infants were randomly assigned to receive deferred therapy, and 252 infants were randomly assigned to receive early therapy. After a median follow-up of 40 weeks (interquartile range, 24 to 58), antiretroviral therapy was initiated in 66% of infants in the deferred-therapy group. Twenty infants in the deferred-therapy group (16%) died versus 10 infants in the early-therapy groups (4%) (hazard ratio for death, 0.24; 95% confidence interval [CI], 0.11 to 0.51; P<0.001). In 32 infants in the deferred-therapy group (26%) versus 16 infants in the early-therapy groups (6%), disease progressed to Centers for Disease Control and Prevention stage C or severe stage B (hazard ratio for disease progression, 0.25; 95% CI, 0.15 to 0.41; P<0.001). Stavudine was substituted for zidovudine in four infants in the early-therapy groups because of neutropenia in three infants and anemia in one infant; no drugs were permanently discontinued. After a review by the data and safety monitoring board, the deferred-therapy group was modified, and infants in this group were all reassessed for initiation of antiretroviral therapy.
Conclusions
Early HIV diagnosis and early antiretroviral therapy reduced early infant mortality by 76% and HIV progression by 75%. (ClinicalTrials.gov number, NCT00102960.)
Media in This Article
Figure 1
Screening and Enrollment.Figure 2
Time to Initiation of Antiretroviral Therapy in the Deferred-Therapy Group.Article Activity
- Article
Infants with human immunodeficiency virus type 1 (HIV-1) infection have higher rates of disease progression and mortality than older children,1-3 even with a high percentage of CD4 lymphocytes (CD4 percentage).4 Whereas early initiation of antiretroviral therapy may be appropriate for infants, continuing treatment for life is problematic, given the limitations of the available drugs, the long-term toxicity of antiretroviral therapy, adherence issues, the risk of resistance to antiretroviral therapy, and limited resources. This trial addresses the optimal time of initiation and duration of antiretroviral therapy in infants with in utero or intrapartum HIV-1 infection. We hypothesized that early initiation of limited antiretroviral therapy soon after primary infection, when the immune system is most immature, would be beneficial and would delay the time to initiation of continuous antiretroviral therapy. In accordance with the recommendation, in June 2007, of the the data and safety monitoring board, we report the early outcomes for infants who were randomly assigned to receive deferred therapy as compared with those assigned to receive early antiretroviral therapy.
Methods
Study Design
The Children with HIV Early Antiretroviral Therapy (CHER) trial is a phase 3, randomized, open-label trial conducted by the Comprehensive International Program for Research in AIDS — South Africa in collaboration with the Medical Research Council Clinical Trials Unit, United Kingdom, and the Division of AIDS (DAIDS) of the National Institutes of Health (NIH). The study is being conducted in two centers in South Africa: the Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, in Soweto, and the Children's Infectious Diseases Clinical Research Unit, Tygerberg Children's Hospital, in Cape Town.
We enrolled infants 6 to 12 weeks of age who had HIV infection (defined by a positive polymerase-chain-reaction [PCR] test for HIV-1 DNA and a plasma HIV-1 RNA level on PCR of >1000 copies per milliliter) and a CD4 percentage of 25% or more. Exclusion criteria are listed in the Supplementary Appendix, available with the full text of this article at www.nejm.org. Infants were randomly assigned to receive one of three treatments: early limited antiretroviral therapy for 96 weeks, early limited antiretroviral therapy for 40 weeks, or deferred therapy. Immunologic criteria for initiating antiretroviral therapy in the deferred-therapy group or reinitiating antiretroviral therapy in the early-therapy groups were a CD4 percentage of less than 20%5 or, in the case of children younger than 12 months, a CD4 percentage of less than 25% or a CD4 count of less than 1000 cells per cubic millimeter, according to World Health Organization (WHO) guidelines updated in 2006.6 Clinical criteria for initiating or reinitiating antiretroviral therapy7 were Centers for Disease Control and Prevention (CDC) stage C or investigator-selected (severe) stage B events (see the Supplementary Appendix), including symptomatic lymphoid interstitial pneumonitis, bronchiectasis, nephropathy, cardiomyopathy, and failure to thrive. GlaxoSmithKline provided lamivudine and zidovudine, and the South African Department of Health provided lopinavir–ritonavir. Written informed consent was obtained from the parents or legal guardians of all the infants. The authors vouch for the completeness and accuracy of the data.
Study Treatment
First-line antiretroviral therapy consisted of zidovudine at a dose of 240 mg per square meter of body-surface area twice daily and lamivudine at a dose of 4 mg per kilogram of body weight twice daily, with lopinavir–ritonavir given at a dose of 300 mg of lopinavir plus 75 mg of ritonavir per square meter twice daily until 6 months of age,8 then at a dose of 230 mg of lopinavir plus 57.5 mg of ritonavir per square meter twice daily. The second-line regimen was predefined and consisted of didanosine, abacavir, and nevirapine (or efavirenz instead of nevirapine if the child was older than 3 years of age). The criteria for switching to second-line therapy are listed in the Supplementary Appendix.
Screening, Randomization, and Follow-up
Infants who were exposed to HIV were identified from programs for the prevention of mother-to-child transmission of HIV-1 in the Western Cape and Gauteng provinces. PCR for HIV-1 DNA was performed from 4 weeks of age when cotrimoxazole prophylaxis commenced. In Gauteng, the regimen for the prevention of mother-to-child transmission of HIV-1 was single-dose nevirapine administered to both the mother and the neonate; in the Western Cape, the regimen was zidovudine administered to mothers from 34 weeks' gestation and to neonates for 7 days and single-dose nevirapine administered to both.
The randomization schedule was prepared centrally by the trial statistician and faxed to the study sites. Randomization was stratified according to clinical center, and blocks, varying randomly in size, were used to ensure balance in the number of infants assigned to each group according to center.
After randomization, the infants were seen every 4 weeks until week 24, then every 8 weeks until week 48, and every 12 weeks thereafter. At each scheduled visit, the evaluation included documentation of any HIV-related clinical events, a complete blood count with a differential count, measurements of aminotransferase levels, and a CD4 cell count with calculation of the CD4 percentage. The pharmacist at each site measured adherence to the assigned medication by comparing the amount of drug dispensed with that returned at the subsequent visit. Toxicity was graded according to the criteria of the DAIDS9 of the National Institute of Allergy and Infectious Diseases (NIAID), at the NIH. The study was also conducted under a Food and Drug Administration investigational-new-drug application (number 71,494).
Outcomes
The primary outcome was the time to death or failure of the first-line antiretroviral therapy. The latter was defined as any of the following: failure to reach a CD4 percentage of 20% or more by week 24 of therapy or a decrease in the CD4 percentage to less than 20% after the first 24 weeks of antiretroviral therapy (immunologic failure), severe CDC stage B or stage C events (clinical failure), or toxicity requiring more than one drug substitution within the same class or a switch to a new class or requiring permanent discontinuation of treatment (i.e., regimen-limiting toxicity failure). An independent end-point review committee reviewed all deaths and CDC stage C and severe stage B events without knowledge of CD4 values, status of antiretroviral therapy, or randomized treatment assignments. Investigators at each of the two centers remained unaware of the primary and secondary outcomes at the other center.
Review and Monitoring
The trial was approved by the ethics committees of both participating institutions. According to the protocol, the study is reviewed at least annually by the independent DAIDS international data and safety monitoring board of Africa; this board can recommend termination or modification of the study because of safety or efficacy concerns. The guiding statistical criterion for “proof beyond reasonable doubt” is based on a difference of at least 3 SD in the log relative hazard (or nominal P<0.001) in any interim analysis (according to the Haybittle–Peto rule). Two such annual reviews have been conducted. In addition, a subcommittee of the data and safety monitoring board reviews all deaths according to randomized treatment assignments and can call for an unscheduled review by the full data and safety monitoring board if there are any safety concerns; the subcommittee has performed three reviews (approximately every 3 months).
At the second annual review of the data and safety monitoring board, in June 2007, by which time accrual had been completed, strong evidence of a difference in mortality emerged between infants who had been randomly assigned to receive early antiretroviral therapy and those assigned to the deferred-therapy regimen. The data and safety monitoring board recommended dissemination of these early findings and urgent evaluation of children in the deferred-therapy group who were not receiving antiretroviral therapy for possible initiation of antiretroviral therapy. The board also recommended that all three groups be continued, with modification in the deferred-therapy group as mentioned above.
Statistical Analysis
The sample size was estimated with the use of the methods previously developed for sample size and estimation of statistical power in complex clinical trials.10,11 We assumed that the cumulative probability of death or regimen failure in the deferred-therapy group would be 0.06, 0.17, 0.28, 0.39, and 0.49 by years 1, 2, 3, 4, and 5, respectively. We assumed that for the first 5 years of follow-up, the annual hazard ratio for disease progression or death would be 0.51, 0.57, 0.78, 0.85, and 0.88 in the group that received early limited antiretroviral therapy for 40 weeks and 0.51, 0.27, 0.43, 0.67, and 0.74 in the group that received early limited antiretroviral therapy for 96 weeks, as compared with the deferred-therapy group. These assumptions were based on estimates of death rates, time to initiation of antiretroviral therapy, and time to failure of antiretroviral therapy in other pediatric cohorts.4,12 Under these assumptions, the planned sample size of 375 children (125 per group), enrolled over a period of 18 months and followed for a minimum of 3.5 years, would provide 80% power to reject the null hypothesis of no difference among the three groups in the time to the primary outcome, on the basis of a global log-rank test with a two-sided alpha level of 0.05.
The planned primary analysis was to first test the null hypothesis of no difference among the three groups in the time to death or regimen failure by means of a global log-rank test with two degrees of freedom (with stratification according to site). If the null hypothesis was rejected, then each of the early-therapy groups was to be compared with the deferred-therapy group in terms of the average hazard during the follow-up period with the use of a Cox proportional-hazards model, also stratified according to site. Although pairwise comparisons of all groups were performed, we report the comparison of the deferred-therapy group with the combined early-therapy groups, preserving blinding between the early-therapy groups, as recommended by the data and safety monitoring board. All analyses are based on complete data as of June 20, 2007.
We used the intention-to-treat approach to compare the early-therapy groups combined with the deferred-therapy group. Time-to-event methods (i.e., Kaplan–Meier plots and the log-rank test stratified according to site) were used to compare the two groups for the time to the primary end point and survival. Cox proportional-hazards modeling was used to estimate a summary hazard ratio for death or treatment failure for the early-therapy groups combined as compared with the deferred-therapy group. The frequency of grade 3 or 4 adverse events in the two groups was compared with the use of a chi-square test. The time to initiation of continuous antiretroviral therapy in the deferred-therapy group was estimated with the use of Kaplan–Meier methods. Changes in the CD4 percentage and the CD4 count over time were summarized with the use of point estimates of mean changes from baseline documented at each visit. All reported P values are two-sided and have not been adjusted for multiple testing.
Results
Of 5985 infants born to mothers in programs for the prevention of mother-to-child transmission of HIV-1, 405 were HIV-positive (6.8%). The transmission rate was higher in Soweto (8.4%) than in Cape Town (5.6%), probably because of different regimens for the prevention of mother-to-child transmission of HIV-1. An additional 155 HIV-infected infants were referred from other infant diagnosis programs. Among 560 HIV-infected infants considered for the trial, 110 were ineligible because the CD4 percentage was less than 25%, and 45 were ineligible for other reasons (Figure 1Figure 1
Screening and Enrollment.). Between August 2005 and February 2007, a total of 377 infants were enrolled; 125 infants were randomly assigned to the deferred-therapy group, and 252 infants were randomly assigned to the early-therapy groups. Two pairs of twins were enrolled: the first pair underwent randomization, and the second pair of twins were nonrandomly assigned to the same group.The median follow-up as of June 20, 2007, was 40 weeks (interquartile range, 24 to 58). Baseline characteristics were well matched in the study groups (Table 1Table 1
Baseline Characteristics of Infants Enrolled in the Trial.). A total of 14% of the infants were breast-fed. Most mothers (62%) and infants (51%) received single-dose nevirapine for the prevention of mother-to-child transmission of HIV-1; 20% of the mothers and 27% of the infants received zidovudine and nevirapine. A smaller proportion (11% of the mothers and 16% of the infants) received no prophylaxis for the prevention of mother-to-child transmission of HIV-1.Follow-up
Treatment was not completed in 14 infants in the early-therapy groups (6%) and in 4 infants in the deferred-therapy group (3%). The reasons were withdrawal of consent, for three infants in the early-therapy groups (1.2%) and for one infant in the deferred-therapy group (0.8%), and loss to follow-up, for the other 14 infants.
In the early-therapy groups, infants received antiretroviral therapy for 99% of the follow-up period, and in the deferred-therapy group, infants received antiretroviral therapy for 35% of the follow-up period. Eighty-three children in the deferred-therapy group (66%) started antiretroviral therapy according to the protocol criteria (63% met immunologic criteria and 36% met clinical criteria); 51 of these children (41%) were younger than 26 weeks of age. The estimated median time to the initiation of antiretroviral therapy in the deferred-therapy group was 21.1 weeks (Figure 2Figure 2
Time to Initiation of Antiretroviral Therapy in the Deferred-Therapy Group.). The adherence rate, defined as the percentage of drug received, was 87.8% for zidovudine, 90.2% for lamivudine, and 92.1% for lopinavir–ritonavir.Mortality and Failure of the First Regimen
Thirty-two infants reached the primary end point of death or failure of the first regimen: 11 of 252 infants in the early-therapy groups combined and 21 of 125 in the deferred-therapy group (hazard ratio for early therapy as compared with deferred therapy, 0.25; 95% confidence interval [CI], 0.12 to 0.51). A total of 30 of 32 primary end points were deaths: 10 of 252 infants in the early-therapy groups (4%) died and 20 of 125 infants in the deferred-therapy group (16%) died (hazard ratio, 0.24; 95% CI, 0.11 to 0.51; P<0.001) (Figure 3AFigure 3
Probability of Death or a First Event, According to Treatment Group. and Table 2Table 2
Mortality Rates.). Average rates of death were 5 per 100 person-years in the early-therapy groups and 21 per 100 person-years in the deferred-therapy group (Table 2). The death rate was much higher in the first 26 weeks after randomization and declined thereafter in both groups (Table 2); 20 of 30 infants died before 26 weeks of age. Fifteen infants in the deferred-therapy group died before receiving antiretroviral therapy; the other 5 infants received antiretroviral therapy, but death occurred within 1 month after initiation of antiretroviral therapy in four of five infants.A total of 12 children (40%) died at home: 8 in the deferred-therapy group (6.4%) versus 4 in the early-therapy groups (1.6%); most deaths were unexpected and rapid. The cause of death was determined in two patients: one had gastroenteritis and one had disseminated tuberculosis. The cause of death was not determined in the remaining 10 infants. Hospital deaths were due to gastroenteritis (in five infants in the deferred-therapy group [4%] vs. four infants in the early-therapy groups [1.6%]), pneumonia (in four infants in the deferred-therapy group), Pneumocystis jiroveci pneumonia (in two infants in the deferred-therapy group), cytomegalovirus (CMV) (in one infant in the deferred-therapy group), liver failure (granulomatous steatohepatitis detected on postmortem examination in one infant in an early-therapy group), and the sudden infant death syndrome (in one infant in an early-therapy group).
HIV Disease Progression
Disease progression occurred in 16 infants in the early-therapy groups (6.3%), as compared with 32 infants in the deferred-therapy group (25.6%) (hazard ratio, 0.25; 95% CI, 0.15 to 0.41; P<0.001) (Table 3Table 3
Adverse Events.). P. jiroveci pneumonia, CMV disease, and esophageal candidiasis occurred only in the deferred-therapy group. Four children had P. jiroveci pneumonia (two cases were definitive and two were presumptive). Failure to thrive was the most common event in both the deferred-therapy group and the early-therapy groups. The time to death or of the first CDC stage C or severe stage B event is shown in Figure 3B. Forty-one infants in the early-therapy groups were hospitalized (16.3%), as compared with 46 infants in the deferred-therapy group (36.8%) (Table 3).Change in the CD4 Percentage during Follow-up
The mean changes from baseline in the CD4 percentage were as follows: at 12 weeks, +4.8% in the early-therapy groups versus −7.5% in the deferred-therapy group (absolute difference between the early-therapy groups and the deferred-therapy group, 12.3%; P<0.001); at 24 weeks, +5.9% versus −5.6% (absolute difference, 11.5%, P<0.001); at 32 weeks, +4.5% versus −4.8% (absolute difference, 9.3%; P<0.001); by week 40, when antiretroviral therapy had been initiated in more infants in the deferred-therapy group, the between-group difference had decreased to 6.7%.
Grade 3 and 4 Drug-Related Events
Of 58 grade 3 or 4 laboratory abnormalities, 20 were related to antiretroviral therapy and occurred in 19 children (Table 3). Fifteen of these children were in the early-therapy groups, and four were in the deferred-therapy group. In the early-therapy groups, neutropenia occurred in 10 children, anemia in 3, and elevated aminotransferase levels in 2. In the deferred-therapy group, three infants had neutropenia and one had elevated aminotransferase levels. Four children, all in the early-therapy groups, switched from zidovudine to stavudine because of neutropenia (in three children) or anemia and neutropenia (in one). No other drugs were discontinued.
Discussion
These data show that antiretroviral therapy initiated at a median age of 7 weeks reduced early mortality from 16% to 4% as compared with antiretroviral therapy initiated according to a threshold CD4 percentage or clinical progression of HIV disease; this is a relative reduction of 76%. A rapid decrease in CD4 values, rapid disease progression, and sudden death were all evident among infants in the deferred-therapy group, despite very close follow-up and regular CD4 monitoring. Although 66% of infants in this group received antiretroviral therapy, mainly because of a decreasing CD4 percentage, excess deaths could not be prevented. Another, smaller South African trial showed similarly rapid decreases in the CD4 percentage, with 85% of infants meeting the criteria for initiation of antiretroviral therapy (i.e., CD4 percentage <20%) by 6 months of age.14
More than one third of deaths in our study occurred at home, before caregivers recognized the need for medical attention. Mortality was consistently higher among infants in the deferred-therapy group than among those in the early-therapy groups throughout the first year of life, although differences were greatest among the youngest infants. Despite the randomization of only asymptomatic infants with high CD4 percentages, the majority of deaths occurred within 6 months after randomization. In 27 of the 30 deaths, there were no antecedent CDC stage C or severe stage B events, and the infants died rapidly from the first significant clinical event, most commonly gastroenteritis or pneumonia. Deaths due to gastroenteritis occurred twice as frequently in the deferred-therapy group as in the early-therapy groups, suggesting that early antiretroviral therapy has a protective effect in infants in whom replacement feeding is common. Whether breast-feeding would have an additional beneficial effect remains to be investigated. Safe infant-feeding practices were promoted, irrespective of the feeding choice. Failure to thrive was twice as frequent in the deferred-therapy group as in the early-therapy groups; however, the occurrence of failure to thrive in infants receiving antiretroviral therapy underscores the importance of nutritional, caregiving, and social factors in these patients.
Although the logistics of HIV testing in early infancy were considerable, the low mother-to-child transmission rate (6.8%) in field conditions highlights the success of programs for the prevention of this type of transmission in the areas where the study was conducted. The timing of HIV infection — in utero or during the perinatal period — is unknown, since the first PCR test was performed at 4 weeks of age. The fact that the majority of the children became infected despite the use of regimens for the prevention of mother-to-child transmission suggests that many of the infections were acquired in utero and that such infections may have contributed to the high rates of rapid progression.15 More rapid disease progression has also been reported among infants infected with HIV despite the use of regimens to prevent mother-to-child transmission of HIV-1 in countries with sufficient resources.16 Our sample size limits comparisons of HIV disease progression among infants in the deferred-therapy group according to whether or not they had received a regimen for the prevention of mother-to-child transmission of HIV-1.
Luzuriaga et al. found better HIV suppression in infants who began to receive antiretroviral therapy before 3 months of age than in infants who began to receive this therapy later.17 A number of U.S. and European cohort studies have reported better outcomes in infants receiving early antiretroviral therapy. However, interpretation of the data may be biased by the lack of randomization.18-21 The HIV Paediatric Prognostic Markers Collaborative Study (HPPMCS),4 a meta-analysis of data from untreated HIV-infected children in the United States and Europe, showed a risk of death that was increased by a factor of six for a 1-year-old child with high CD4 values as compared with a child 5 years of age with high CD4 values. The Cross Continents Collaboration for Kids study of untreated HIV-infected African children showed a poorer predictive value of CD4 values in young children after infancy and much higher mortality rates than those reported in the HPPMCS.22 Current guidelines recommend the initiation of antiretroviral therapy on the basis of a low CD4 percentage or count, a high viral load, or the presence of clinical symptoms, whereas the treatment of asymptomatic infants with high CD4 values is not mandated. Results from the CHER trial provide support for early antiretroviral therapy to reduce mortality among infants who acquire HIV infection despite regimens for the prevention of mother-to-child transmission of HIV-1.6,23-25
In the CHER trial, infants received a protease inhibitor–based regimen as first-line antiretroviral therapy, according to South-African guidelines. A nevirapine-based regimen may not be advisable for early treatment in infants exposed to single-dose nevirapine.26 Since guidelines for most resource-limited countries recommend starting antiretroviral therapy with nevirapine, the implementation of early antiretroviral therapy may pose considerable challenges. The estimated probability of death in the deferred-therapy group (17%) is lower than the 35% probability reported in African birth cohorts before the introduction of antiretroviral therapy or widespread cotrimoxazole prophylaxis.3 By comparison, early natural-history studies in the United States and Europe showed mortality that was lower but rates of disease progression that were similar to the rates among infants in the deferred-therapy group in our study.2,27
These data provide strong support for the initiation of antiretroviral therapy from an early age, regardless of the CD4 percentage or count. A good program for the prevention of mother-to-child transmission of HIV-1, encompassing early diagnosis in infants, is fundamental to the success of any early antiretroviral-therapy strategy.
Supported by a grant from the National Institute of Allergy and Infectious Diseases of the National Institutes for Health through the Comprehensive International Program of Research on AIDS network (U19 AI53217); the Departments of Health of the Western Cape and Gauteng, South Africa; and GlaxoSmithKline.
The views expressed in this report do not necessarily reflect the views or policies of the National Institute of Allergy and Infectious Diseases, nor does mention of trade names, commercial projects, or organizations imply endorsement by the U.S. government.
Drs. Violari and Cotton report receiving lecture fees from Abbott Laboratories; Dr. Babiker, research support from Abbott Laboratories; and Dr. Gibb, research support from the Meningitis Research Foundation, GlaxoSmithKline, and Gilead. No other potential conflict of interest relevant to this article was reported.
We thank the families and children who participated in the trial.
Source Information
From the Perinatal HIV Research Unit (A.V., J.S., J.A.M.) and the Department of Science and Technology, National Research Foundation: Vaccine Preventable Diseases (S.A.M.), University of the Witwatersrand, Johannesburg; and the Children's Infectious Diseases Clinical Research Unit, Faculty of Health Sciences, Stellenbosch University, Tygerberg (M.F.C.) — both in South Africa; Medical Research Council Clinical Trials Unit, London (D.M.G., A.G.B.); and the Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD (P.J.-P.).
Address reprint requests to Dr. Violari at the Perinatal HIV Research Unit, University of the Witwatersrand, P.O. Box 114, Johannesburg 1864, South Africa, or at violari@mweb.co.za.
The members of the Children with HIV Early Antiretroviral Therapy (CHER) study team are listed in the Appendix.
Appendix
The following investigators, clinical centers, and committees participated in the Children with HIV Early Antiretroviral Therapy (CHER) trial: South Africa — A. Violari, J. McIntyre, W. Pelser, J. Steyn, S. Madhi, A. Naeem-Sheik, M. Budge, M. Saleh, S. Cassimjee, E. Lazarus, S. Mashinini, S. Dlamini, V. Kemese, J. Bolton (Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg); M.F. Cotton, H. Rabie, A. Janse van Rensburg, E. Dobbels, G. Fourie, M. Bester, W. Orange, R. Arendze, C. Andrea, M. Smuts, K. Smith, T. Louw, A. Abrahams, K. Kelly, A. Bohle, I. Mong, J. Howard, T. Cyster, G. Solomon, G. Benjamin, J. Mkalipi, E. Barnes (Children's Infectious Diseases Clinical Research Unit, Stellenbosch University, Tygerberg); I. Sanne, G. Gray, R. Panchia, C. Davies, M. Cornell (Comprehensive International Program for Research in AIDS — South Africa [CIPRA-SA]); W. Stevens, D. Glencross (CIPRA-SA Laboratory Core); S. Spector, C. van der Horst (CIPRA-SA Scientific Advisory Committee); United Kingdom — A.G. Babiker, D.M. Gibb, (Medical Research Council, Clinical Trials Unit [MRC CTU], London) J.-M. Steens, W.X. Snowden, N. Thoofer, E. Loeliger (GlaxoSmithKline); United States — E. Handelsman, K. Reese, P. Jean-Phillipe, J. Nadler (Division of Acquired Immunodeficiency Syndrome, National Institute of Allergy and Infectious Diseases [NIAID], National Institutes of Health [NIH]), J. McNamara (Division of Allergy, Immunology, and Transplantation, NIAID, NIH), R. Hoff (Regional Emerging Diseases Intervention Center), S. Lehrman (Merck), C. Oster (Walter Reed Army Institute of Research). End Point and Clinical Events Review Committee: T. Peto (chair) (John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom); L. Levin (Right to Care, Johannesburg); D. Gibb (MRC CTU, London). Data Safety and Monitoring Board: S. Ellenberg (chair) (University of Pennsylvania, Philadelphia); R. DerSimonian (executive secretary); A. Dodoo (University of Ghana, Accra); D. Harrington (Harvard School of Public Health, Boston); A. Kamali (MRC Uganda, Entebbe); E. Katabira (Makerere University Uganda, Kampala); C. Lombard (MRC South Africa, Cape Town); C. Luo (UNICEF, New York); M.F. Marshall (University of Minnesota, Minneapolis); L. Mokgatlhe (University of Botswana, Gaborone); A. Mwinga (Centers for Disease Control Zambia, Lusaka); A. Nunn (MRC CTU, London); H. Saloojee (University of the Witwatersrand, Johannesburg); M. Sande (University of Washington, Seattle); J. Schoeman (Stellenbosch University, Tygerberg, South Africa); J. Singh (Nelson Mandela School of Medicine, Durban); R. Boss-Victoria (Bowie State University, Bowie, MD); T. Chipato (University of Zimbabwe, Harare); S. Emerson (University of Washington, Seattle); J. Mfutso-Bengo (University of Malawi, Blantyre); and P. Mwaba (University of Zambia, Lusaka).
- References
References
1
Diaz C ,Hanson C ,Cooper ER , et al. Disease progression in a cohort of infants with vertically acquired HIV infection observed from birth: the Women and Infants Transmission Study (WITS). J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:221-228
CrossRef | Medline2
Tovo PA ,de Martino M ,Gabiano C , et al. Prognostic factors and survival in children with perinatal HIV-1 infection: the Italian register for HIV infections in children. Lancet 1992;339:1249-1253
CrossRef | Web of Science | Medline3
Newell ML ,Coovadia H ,Cortina-Borja M ,Rollins N ,Gaillard P ,Dabis F . Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 2004;364:1236-1243
CrossRef | Web of Science | Medline4
Dunn D . Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. Lancet 2003;362:1605-1611
CrossRef | Web of Science | Medline5
Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach. Geneva: World Health Organization, 2002.
6
Antiretroviral therapy for HIV infection in infants and children: towards universal access — recommendations for a public health approach. Geneva: World Health Organization, 2006.
7
Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Morb Mortal Wkly Rep 1994;43:1-10
Medline8
Chadwick EG ,Capparelli EV ,Yogev R , et al. Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results. AIDS 2008;22:249-255
CrossRef | Web of Science | Medline9
National Institute of Allergy and Infectious Diseases, Division of AIDS. Table for grading the severity of adult and pediatric adverse events. December, 2004.
10
Barthel FM ,Babiker A ,Royston P ,Parmar MK . Evaluation of sample size and power for multi-arm survival trials allowing for non-uniform accrual, non-proportional hazards, loss to follow-up and cross-over. Stat Med 2006;25:2521-2542
CrossRef | Web of Science | Medline11
Royston P ,Babiker A . Complex sample size calculation in randomised controlled trials with a survival or binary outcome. Stata J 2002;2:151-16312
Paediatric European Network for Treatment of AIDS (PENTA)
CrossRef | Web of Science | Medline13
WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. Geneva: World Health Organization, 2007:20.
14
Mphatswe W ,Blanckenberg N ,Tudor-Williams G , et al. High frequency of rapid immunological progression in African infants infected in the era of perinatal HIV prophylaxis. AIDS 2007;21:1253-1261
CrossRef | Web of Science | Medline15
Mayaux MJ ,Burgard M ,Teglas JP , et al. Neonatal characteristics in rapidly progressive perinatally acquired HIV-1 disease. JAMA 1996;275:606-610
CrossRef | Web of Science | Medline16
Kuhn L ,Abrams EJ ,Weedon J , et al. Disease progression and early viral dynamics in human immunodeficiency virus-infected children exposed to zidovudine during prenatal and perinatal periods. J Infect Dis 2000;182:104-111
CrossRef | Web of Science | Medline17
Luzuriaga K ,McManus M ,Mofenson L ,Britto P ,Graham B ,Sullivan JL . A trial of three antiretroviral regimens in HIV-1-infected children. N Engl J Med 2004;350:2471-2480
Full Text | Web of Science | Medline18
Berk DR ,Falkovitz-Halpern MS ,Hill DW , et al. Temporal trends in early clinical manifestations of perinatal HIV infection in a population-based cohort. JAMA 2005;293:2221-2231
CrossRef | Web of Science | Medline19
Chiappini E ,Galli L ,Tovo PA , et al. Virologic, immunologic, and clinical benefits from early combined antiretroviral therapy in infants with perinatal HIV-1 infection. AIDS 2006;20:207-215[Erratum, AIDS 2006;20:1789.]
CrossRef | Web of Science | Medline20
Faye A ,Le Chenadec J ,Dollfus C , et al. Early versus deferred antiretroviral multidrug therapy in infants infected with HIV type 1. Clin Infect Dis 2004;39:1692-1698
CrossRef | Web of Science | Medline21
Goetghebuer T, Haelterman E, Chenadec J, et al. Early versus deferred highly active antiretroviral therapy in HIV infected infants: a European collaborative cohort study. In: IV Dominique DORMONT International Conference, Paris, December 13-15, 2007.
22
Cross Continents Collaboration for Kids (3Cs4Kids) Analysis and Writing Committee
CrossRef | Web of Science | Medline23
Sharland M ,Blanche S ,Castelli G ,Ramos J ,Gibb DM . PENTA guidelines for the use of antiretroviral therapy, 2004. HIV Med 2004;5:Suppl 2:61-86
CrossRef | Web of Science | Medline24
Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Bethesda, MD: Department of Health and Human Services, October 26, 2006. (Accessed October 26, 2008, at http://aidsinfo.nih.gov.)
25
National Department of Health. National antiretroviral treatment guidelines. Pinetown, South Africa: Jacana Publishers, 2004.
26
Lockman S ,Shapiro RL ,Smeaton LM , et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007;356:135-147
Full Text | Web of Science | Medline27
Abrams EJ ,Wiener J ,Carter R , et al. Maternal health factors and early pediatric antiretroviral therapy influence the rate of perinatal HIV-1 disease progression in children. AIDS 2003;17:867-877
CrossRef | Web of Science | Medline
- Citing Articles (181)
Citing Articles
1
T. A. Wagner, L. M. Frenkel. (2012) Yet Another Reason to Treat HIV Infection. Clinical Infectious Diseases
CrossRef2
Jean Maritz, Wolfgang Preiser, Gert U. van Zyl. (2012) Establishing diagnostic cut-off criteria for the COBAS AmpliPrep/COBAS TaqMan HIV-1 Qualitative test through validation against the Amplicor DNA test v1.5 for infant diagnosis using dried blood spots. Journal of Clinical Virology 53:2, 106-109
CrossRef3
Shirin Heidari, Lynne M. Mofenson, Charlotte V. Hobbs, Mark F. Cotton, Richard Marlink, Elly Katabira. (2012) Unresolved Antiretroviral Treatment Management Issues in HIV-Infected Children. JAIDS Journal of Acquired Immune Deficiency Syndromes 59:2, 161-169
CrossRef4
Maria H. Kim, Carrie Cox, Anjalee Dave, Heather R. Draper, Mark Kabue, Gordon E. Schutze, Saeed Ahmed, Peter N. Kazembe, Mark W. Kline, Mark Manary. (2012) Prompt Initiation of ART With Therapeutic Food Is Associated With Improved Outcomes in HIV-Infected Malawian Children With Malnutrition. JAIDS Journal of Acquired Immune Deficiency Syndromes 59:2, 173-176
CrossRef5
P. G. D. Navaneethapandian, R. Karunaianantham, S. Subramanyan, P. Chinnayan, P. Chandrasekaran, S. Swaminathan. (2012) CD4+ T-Lymphocyte Count /CD8+ T-Lymphocyte Count Ratio: Surrogate for HIV Infection in Infants?. Journal of Tropical Pediatrics
CrossRef6
Charlotte Charpentier, Jean-Chrysostome Gody, Olivia Mbitikon, Sandrine Moussa, Mathieu Matta, Hélène Péré, Julien Fournier, Jean De Dieu Longo, Laurent Bélec. (2012) Virological Response and Resistance Profiles After 18 to 30 Months of First- or Second-/Third-Line Antiretroviral Treatment: A Cross-Sectional Evaluation in HIV Type 1-Infected Children Living in the Central African Republic. AIDS Research and Human Retroviruses 28:1, 87-94
CrossRef7
Koen K.A. Van Rompay. (2012) The Use of Nonhuman Primate Models of HIV Infection for the Evaluation of Antiviral Strategies. AIDS Research and Human Retroviruses 28:1, 16-35
CrossRef8
Marianne Burgard, Stéphane Blanche, Carine Jasseron, Philippe Descamps, Marie-Christine Allemon, Nicole Ciraru-Vigneron, Corinne Floch, Brigitte Heller-Roussin, Eric Lachassinne, Fabienne Mazy, Josiane Warszawski, Christine Rouzioux. (2012) Performance of HIV-1 DNA or HIV-1 RNA Tests for Early Diagnosis of Perinatal HIV-1 Infection during Anti-Retroviral Prophylaxis. The Journal of Pediatrics 160:1, 60-66.e1
CrossRef9
Mark R. Schleiss, Janna C. Patterson. 2012. Viral Infections of the Fetus and Newborn and Human Immunodeficiency Virus Infection during Pregnancy. , 468-512.
CrossRef10
Rohan Hazra, Rachel A. Cohen, René Gonin, Jacqueline P. Monteiro, Cristina B. Hofer, Marinella D. Negra, Noris P. Ruz. (2012) Lipid levels in the second year of life among HIV-infected and HIV-exposed uninfected Latin American children. AIDS 26:2, 235-240
CrossRef11
Amin S. Hassan, Erick M. Sakwa, Helen M. Nabwera, Miriam M. Taegtmeyer, Robert M. Kimutai, Eduard J. Sanders, Ken K. Awuondo, Maureen N. Mutinda, Catherine S. Molyneux, James A. Berkley. (2012) Dynamics and Constraints of Early Infant Diagnosis of HIV Infection in Rural Kenya. AIDS and Behavior 16:1, 5-12
CrossRef12
Amy S. Sturt, Meira S. Halpern, Barbara Sullivan, Yvonne A. Maldonado. (2012) Timing of Antiretroviral Therapy Initiation and its Impact on Disease Progression in Perinatal Human Immunodeficiency Virus-1 Infection. The Pediatric Infectious Disease Journal 31:1, 53-60
CrossRef13
T. Sonia Boender, Kim C. E. Sigaloff, Joshua Kayiwa, Victor Musiime, Job C. J. Calis, Raph L. Hamers, Lillian Katumba Nakatudde, Elizabeth Khauda, Andrew Mukuye, James Ditai, Sibyl P. Geelen, Peter Mugyenyi, Tobias F. Rinke de Wit, Cissy Kityo. (2012) Barriers to Initiation of Pediatric HIV Treatment in Uganda: A Mixed-Method Study. AIDS Research and Treatment 2012, 1-10
CrossRef14
T van den Akker, M Bemelmans, N Ford, M Jemu, E Diggle, S Scheffer, I Zulu, A Akesson, J Shea. (2012) HIV care need not hamper maternity care: a descriptive analysis of integration of services in rural Malawi. BJOG: An International Journal of Obstetrics & Gynaecologyno-no
CrossRef15
T. Goetghebuer, J. Le Chenadec, E. Haelterman, L. Galli, C. Dollfus, C. Thorne, A. Judd, O. Keiser, J. T. Ramos, J. Levy, J. Warszawski, . (2011) Short- and Long-term Immunological and Virological Outcome in HIV-Infected Infants According to the Age at Antiretroviral Treatment Initiation. Clinical Infectious Diseases
CrossRef16
Alberto Novaes Ramos, Luiza Harunari Matida, Norman Hearst, Fabíola Araújo Oliveira, Jorg Heukelbach. (2011) High occurrence of HIV-positive siblings due to repeated mother-to-child transmission in Brazil. AIDS Care1-5
CrossRef17
Maria Isabel de Moraes-Pinto. (2011) Interaction between pediatric HIV infection and measles. Future Virology 6:12, 1471-1479
CrossRef18
Meera K. Chhagan, Shuaib Kauchali, Stephen M. Arpadi, Murray H. Craib, Fatimatou Bah, Zena Stein, Leslie L. Davidson. (2011) Failure to test children of HIV-infected mothers in South Africa: implications for HIV testing strategies for preschool children. Tropical Medicine & International Health 16:12, 1490-1494
CrossRef19
Alberto Novaes Ramos, Luiza Harunari Matida, Norman Hearst, Jorg Heukelbach. (2011) Mortality in Brazilian Children with HIV/AIDS: The Role of Non-AIDS–Related Conditions After Highly Active Antiretroviral Therapy Introduction. AIDS Patient Care and STDs 25:12, 713-718
CrossRef20
Shihai Huang, Brian Erickson, Wai Bing Mak, John Salituro, Klara Abravaya. (2011) A novel RealTime HIV-1 Qualitative assay for the detection of HIV-1 nucleic acids in dried blood spots and plasma. Journal of Virological Methods 178:1-2, 216-224
CrossRef21
Nicole C. Schmidt, José Roman-Pouriet, Aracelis D. Fernandez, Consuelo M. Beck-Sagué, José Leonardo-Guerrero, Stephen W. Nicholas. (2011) Costs and benefits of multidrug, multidose antiretroviral therapy for prevention of mother-to-child transmission of HIV in the Dominican Republic. International Journal of Gynecology & Obstetrics
CrossRef22
B. G. Kapogiannis, M. M. Soe, S. R. Nesheim, E. J. Abrams, R. J. Carter, J. Farley, P. Palumbo, L. J. Koenig, M. Bulterys. (2011) Mortality Trends in the US Perinatal AIDS Collaborative Transmission Study (1986-2004). Clinical Infectious Diseases 53:10, 1024-1034
CrossRef23
S. Nachman. (2011) Highly Active Antiretroviral Treatment and Children. Clinical Infectious Diseases 53:10, 1035-1036
CrossRef24
Martina Penazzato, Carlo Giaquinto. (2011) Role of Non-Nucleoside Reverse Transcriptase Inhibitors in Treating HIV-Infected Children. Drugs 71:16, 2131-2149
CrossRef25
Geoffrey Fatti, Peter Bock, Brian Eley, Eula Mothibi, Ashraf Grimwood. (2011) Temporal Trends in Baseline Characteristics and Treatment Outcomes of Children Starting Antiretroviral Treatment. JAIDS Journal of Acquired Immune Deficiency Syndromes 58:3, e60-e67
CrossRef26
Ann Prentice, Kate Ward, Inez Schoenmakers, Gail Goldberg. 2011. Bone Growth in African Children and Adolescents. .
CrossRef27
M. Brewinski, K. Megazzini, L. Freimanis Hance, M. C. Cruz, N. Pavia-Ruz, M. Della Negra, F. G. F. Ferreira, H. Marques, R. Hazra, . (2011) Dyslipidemia in a Cohort of HIV-infected Latin American Children Receiving Highly Active Antiretroviral Therapy. Journal of Tropical Pediatrics 57:5, 324-332
CrossRef28
Emmanouil Papasavvas, Livio Azzoni, Andrea Foulkes, Avy Violari, Mark F. Cotton, Maxwell Pistilli, Griffin Reynolds, Xiangfan Yin, Deborah K. Glencross, Wendy S. Stevens, James A. McIntyre, Luis J. Montaner. (2011) Increased Microbial Translocation in ≤180 Days Old Perinatally Human Immunodeficiency Virus-positive Infants as Compared With Human Immunodeficiency Virus-exposed Uninfected Infants of Similar Age. The Pediatric Infectious Disease Journal 30:10, 877-882
CrossRef29
David M. le Roux, Mark F. Cotton, Stanzi M. le Roux, Andrew Whitelaw, Carl J. Lombard, Heather J. Zar. (2011) Bacteremia in Human Immunodeficiency Virus-infected Children in Cape Town, South Africa. The Pediatric Infectious Disease Journal 30:10, 904-906
CrossRef30
Gayle G. Sherman, Rivka R. Lilian, Ashraf H. Coovadia. (2011) The Performance of 5 Rapid Human Immunodeficiency Virus Tests Using Whole Blood in Infants and Children. The Pediatric Infectious Disease Journal1
CrossRef31
Barbara S. Taylor, Gillian Hunt, Elaine J. Abrams, Ashraf Coovadia, Tammy Meyers, Gayle Sherman, Renate Strehlau, Lynn Morris, Louise Kuhn. (2011) Rapid Development of Antiretroviral Drug Resistance Mutations in HIV-Infected Children Less Than Two Years of Age Initiating Protease Inhibitor-Based Therapy in South Africa. AIDS Research and Human Retroviruses 27:9, 945-956
CrossRef32
Shabir A. Madhi, Avy Violari, Keith P. Klugman, Gina Lin, James A. McIntyre, Anne von Gottberg, Patrick Jean-Philippe, Mark F. Cotton, Peter Adrian. (2011) Inferior quantitative and qualitative immune responses to pneumococcal conjugate vaccine in infants with nasopharyngeal colonization by Streptococcus pneumoniae during the primary series of immunization. Vaccine 29:40, 6994-7001
CrossRef33
L. BONDIOLI, A. LUDOVISI, G. TOSI, B. RUOZI, F. FORNI, E. POZIO, M. A. VANDELLI, M. A. GÓMEZ-MORALES. (2011) The loading of labelled antibody-engineered nanoparticles with Indinavir increases its in vitro efficacy against Cryptosporidium parvum. Parasitology 138:11, 1384-1391
CrossRef34
Yan Zhao, Weiwei Mu, Joseph Harwell, Haiwei Zhou, Xin Sun, Yuewu Cheng, Chunming Li, Fujie Zhang. (2011) Drug Resistance Profiles Among HIV-1–Infected Children Experiencing Delayed Switch and 12-Month Efficacy After Using Second-Line Antiretroviral Therapy: An Observational Cohort Study in Rural China. JAIDS Journal of Acquired Immune Deficiency Syndromes 58:1, 47-53
CrossRef35
Alberto Novaes Ramos, Luiza Harunari Matida, Norman Hearst, Jorg Heukelbach. (2011) AIDS Morbidity and Mortality in Brazilian Children Before and After Highly Active Antiretroviral Treatment Implementation. The Pediatric Infectious Disease Journal 30:9, 773-777
CrossRef36
Pippa Macdonald, Mhairi Maskew, Denise Evans, Leon Levin, Sanlie Untiedt, Ian Sanne. (2011) Paediatric human immunodeficiency virus treatment outcomes from a resource-limited setting in South Africa: Highly active antiretroviral therapy alone is not enough. Vulnerable Children and Youth Studies 6:3, 208-221
CrossRef37
Christina F. Thobakgale, Hendrik Streeck, Nompumelelo Mkhwanazi, Zenele Mncube, Lungile Maphumulo, Fundisiwe Chonco, Andrew Prendergast, Gareth Tudor-Williams, Bruce D. Walker, Philip J.R. Goulder, Marcus Altfeld, Thumbi Ndung'u. (2011) Short Communication: CD8 + T Cell Polyfunctionality Profiles in Progressive and Nonprogressive Pediatric HIV Type 1 Infection. AIDS Research and Human Retroviruses 27:9, 1005-1012
CrossRef38
Lallemant, Marc, Chang, Shing, Cohen, Rachel, Pecoul, Bernard, . (2011) Pediatric HIV — A Neglected Disease?. New England Journal of Medicine 365:7, 581-583
Full Text39
Taryn N. Green, Mohendran Archary, Michelle L. Gordon, Nagavelli Padayachi, Yolanda Lie, Elizabeth D. Anton, Jacqueline D. Reeves, Anneke Grobler, Raziya Bobat, Hoosen Coovadia, Thumbi Ndung'u. (2011) Drug Resistance and Coreceptor Usage in HIV Type 1 Subtype C-Infected Children Initiating or Failing Highly Active Antiretroviral Therapy in South Africa. AIDS Research and Human Retroviruses110805130806000
CrossRef40
E. D. Nel, H. Rabie, J. Goodway, M. F. Cotton. (2011) A Retrospective Study of Cryptosporidial Diarrhea in a Region with High HIV Prevalence. Journal of Tropical Pediatrics 57:4, 289-292
CrossRef41
Deborah Persaud, Abubaker Bedri, Carrie Ziemniak, Anitha Moorthy, Berhanu Gudetta, Aida Abashawl, Yohannes Mengistu, Saad B. Omer, Abdulhamid Isehak, Solomon Kumbi, Rahel Adamu, Sileshi Lulseged, Roxann Ashworth, Elham Hassen, Andrea Ruff, and the Ethiopian SWEN Study. (2011) Slower Clearance of Nevirapine Resistant Virus in Infants Failing Extended Nevirapine Prophylaxis for Prevention of Mother-to-Child HIV Transmission. AIDS Research and Human Retroviruses 27:8, 823-829
CrossRef42
(2011) Paediatric European Network for Treatment of AIDS response to 2010 revision of World Health Organization recommendations on ‘Antiretroviral therapy for HIV infection in infants and children’. HIV Medicine 12:6, 385-386
CrossRef43
George K Siberry, Kunjal Patel, Russell B Van Dyke, Rohan Hazra, Sandra K Burchett, Stephen A Spector, Mary E Paul, Jennifer S Read, Andrew Wiznia, George R Seage. (2011) CD4+ Lymphocyte-Based Immunologic Outcomes of Perinatally HIV-Infected Children During Antiretroviral Therapy Interruption. JAIDS Journal of Acquired Immune Deficiency Syndromes 57:3, 223-229
CrossRef44
Camille Ndondoki, François Dabis, Leticia Namale, Renaud Becquet, Didier Ekouevi, Clarisse Bosse-Amani, Elise Arrivé, Valériane Leroy. (2011) Survie et évolution clinique et biologique des enfants infectés par le VIH traités par les antiretroviraux en Afrique : revue de littérature, 2004–2009. La Presse Médicale 40:7-8, e338-e357
CrossRef45
Gillian M. Hunt, Ashraf Coovadia, Elaine J. Abrams, Gayle Sherman, Tammy Meyers, Lynn Morris, Louise Kuhn. (2011) HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine. AIDS 25:12, 1461-1469
CrossRef46
Maxime Aimé Oga, Camille Ndondoki, Hermann Brou, Amadou Salmon, Clarisse Bosse-Amani, Marguerite Timite-Konan, Valériane Leroy. (2011) Attitudes and Practices of Health Care Workers Toward Routine HIV Testing of Infants in Côte dʼIvoire: The PEDI-TEST ANRS 12165 Project. JAIDS Journal of Acquired Immune Deficiency Syndromes 57, S16-S21
CrossRef47
M. Hainaut, V. Verscheure, M. Ducarme, L. Schandené, J. Levy, F. Mascart. (2011) Cellular immune responses in human immunodeficiency virus (HIV)-1-infected children: is immune restoration by highly active anti-retroviral therapy comparable to non-progression?. Clinical & Experimental Immunology 165:1, 77-84
CrossRef48
(2011) 30 Years of Pediatric HIV/AIDS Treatment: A Time of Breakthroughs, Innovation. Pediatric Annals 40:7, 340-341
CrossRef49
Eleanor Turnbull, Mwila K. Lembalemba, M. Brad Guffey, Carolyn Bolton-Moore, Mwangelwa Mubiana-Mbewe, Namwinga Chintu, Mark J. Giganti, Mutinta Nalubamba-Phiri, Elizabeth M. Stringer, Jeffrey S. A. Stringer, Benjamin H. Chi. (2011) Causes of stillbirth, neonatal death and early childhood death in rural Zambia by verbal autopsy assessments. Tropical Medicine & International Health 16:7, 894-901
CrossRef50
S. E. Purchase, D. J. Van der Linden, N. H. McKerrow. (2011) Feasibility and Effectiveness of Early Initiation of Combination Antiretroviral Therapy in HIV-infected Infants in a Government Clinic of Kwazulu-Natal, South Africa. Journal of Tropical Pediatrics
CrossRef51
R. Solomons, A. Slogrove, J. Schoeman, B. Marais, G. van Zyl, J. Maritz, R. van Toorn. (2011) Acute Extrapyramidal Dysfunction in Two HIV-infected Children. Journal of Tropical Pediatrics 57:3, 227-231
CrossRef52
Boubacar Nacro, Emmanuelle Zoure, Hervé Hien, Hassane Tamboura, François Rouet, Adama Ouiminga, Ali Drabo, Souleymane Yameogo, Alain Hien, Hélène Peyriere, Olivier Mathieu, Deborah Hirt, Jean-Marc Treluyer, Joëlle Nicolas, Vincent Foulongne, Michel Segondy, Philippe van de Perre, Serge Diagbouga, Philippe Msellati. (2011) Pharmacology and immuno-virologic efficacy of once-a-day HAART in African HIV-infected children: ANRS 12103 phase II trial. Bulletin of the World Health Organization 89:6, 451-458
CrossRef53
Tamsen Jean Rochat, Ruth Bland, Hoosen Coovadia, Alan Stein, Marie-Louise Newell. (2011) Towards a family-centered approach to HIV treatment and care for HIV-exposed children, their mothers and their families in poorly resourced settings. Future Virology 6:6, 687-696
CrossRef54
Eric D. McCollum, Geoffrey A. Preidis, Carrie L. Golitko, Linias D. Siwande, Charles Mwansambo, Peter N. Kazembe, Irving Hoffman, Mina C. Hosseinipour, Gordon E. Schutze, Mark W. Kline. (2011) Routine Inpatient Human Immunodeficiency Virus Testing System Increases Access to Pediatric Human Immunodeficiency Virus Care in Sub-Saharan Africa. The Pediatric Infectious Disease Journal 30:5, e75-e81
CrossRef55
Maunank Shah, Benjamin Johns, Alashʼle Abimiku, Damian G Walker. (2011) Cost-effectiveness of new WHO recommendations for prevention of mother-to-child transmission of HIV in a resource-limited setting. AIDS 25:8, 1093-1102
CrossRef56
Angelika Niemz, Tanya M. Ferguson, David S. Boyle. (2011) Point-of-care nucleic acid testing for infectious diseases. Trends in Biotechnology 29:5, 240-250
CrossRef57
Clàudia Fortuny, Antoni Noguera-Julian, Laia Alsina, Rocío Bellido, Emília Sánchez, Carmen Muñoz-Almagro, Lidia Ruiz, Rafael Jiménez. (2011) IMPACT OF CD4 T CELL COUNT ON THE OUTCOME OF PLANNED TREATMENT INTERRUPTIONS IN EARLY-TREATED HUMAN IMMUNODEFICIENCY VIRUS-INFECTED CHILDREN. The Pediatric Infectious Disease Journal 30:5, 435-438
CrossRef58
(2011) Risk of triple-class virological failure in children with HIV: a retrospective cohort study. The Lancet 377:9777, 1580-1587
CrossRef59
J. Fogel, Q. Li, T. E. Taha, D. R. Hoover, N. I. Kumwenda, L. M. Mofenson, J. J. Kumwenda, M. G. Fowler, M. C. Thigpen, S. H. Eshleman. (2011) Initiation of Antiretroviral Treatment in Women After Delivery Can Induce Multiclass Drug Resistance in Breastfeeding HIV-Infected Infants. Clinical Infectious Diseases 52:8, 1069-1076
CrossRef60
Arman Nabatiyan, Zaheer A. Parpia, Robert Elghanian, David M. Kelso. (2011) Membrane-based plasma collection device for point-of-care diagnosis of HIV. Journal of Virological Methods 173:1, 37-42
CrossRef61
C. F. Houlihan, R. M. Bland, P. C. Mutevedzi, R. J. Lessells, J. Ndirangu, H. Thulare, M.-L. Newell. (2011) Cohort Profile: Hlabisa HIV Treatment and Care Programme. International Journal of Epidemiology 40:2, 318-326
CrossRef62
Maureen Braun, Mark M Kabue, Eric D McCollum, Saeed Ahmed, Maria Kim, Leela Aertker, Marko Chirwa, Michael Eliya, Innocent Mofolo, Irving Hoffman, Peter N Kazembe, Charles van der Horst, Mark W Kline, Mina C Hosseinipour. (2011) Inadequate Coordination of Maternal and Infant HIV Services Detrimentally Affects Early Infant Diagnosis Outcomes in Lilongwe, Malawi. JAIDS Journal of Acquired Immune Deficiency Syndromes 56:5, e122-e128
CrossRef63
Amanda Clarke, Reshmie Ramautarsing, Pirapon June Ohata, Denise Hsu, Nadia Kancheva Landolt, Stephen J Kerr, Anchalee Avihingsanon, Wirach Maek-a-nantawat, Thanyawee Puthanakit, Torsak Bunupuradah, Wasana Prasitsuebsai, Jintanat Ananworanich, Kiat Ruxrungtham. (2011) The 14th Bangkok International Symposium on HIV Medicine. Future Virology 6:4, 409-412
CrossRef64
Jessica Fogel, Donald R Hoover, Jin Sun, Lynne M Mofenson, Mary G Fowler, Allan W Taylor, Newton Kumwenda, Taha E Taha, Susan H Eshleman. (2011) Analysis of nevirapine resistance in HIV-infected infants who received extended nevirapine or nevirapine/zidovudine prophylaxis. AIDS 25:7, 911-917
CrossRef65
K. K. Venkatesh, G. de Bruyn, E. Marinda, K. Otwombe, R. van Niekerk, M. Urban, E. W. Triche, S. T. McGarvey, M. N. Lurie, G. E. Gray. (2011) Morbidity and Mortality among Infants Born to HIV-Infected Women in South Africa: Implications for Child Health in Resource-Limited Settings. Journal of Tropical Pediatrics 57:2, 109-119
CrossRef66
Rebecca E Cook, Philip J Ciampa, Mohsin Sidat, Meridith Blevins, Janeen Burlison, Mario A Davidson, Jorge A Arroz, Alfredo E Vergara, Sten H Vermund, Troy D Moon. (2011) Predictors of Successful Early Infant Diagnosis of HIV in a Rural District Hospital in Zambézia, Mozambique. JAIDS Journal of Acquired Immune Deficiency Syndromes 56:4, e104-e109
CrossRef67
B.J. Marais, H. Rabie, M.F. Cotton. (2011) TB and HIV in children – advances in prevention and management. Paediatric Respiratory Reviews 12:1, 39-45
CrossRef68
Heather J. Zar, Madhukar Pai. (2011) Childhood Tuberculosis – a new era. Paediatric Respiratory Reviews 12:1, 1-2
CrossRef69
Saad B Omer. (2011) Twelve-month follow-up of Six Week Extended Dose Nevirapine randomized controlled trials: differential impact of extended-dose nevirapine on mother-to-child transmission and infant death by maternal CD4 cell count. AIDS 25:6, 767-776
CrossRef70
Ellen G Chadwick, Ram Yogev, Carmelita G Alvero, Michael D Hughes, Rohan Hazra, Jorge A Pinto, Brian L Robbins, Barbara E Heckman, Paul E Palumbo, Edmund V Capparelli. (2011) Long-term outcomes for HIV-infected infants less than 6 months of age at initiation of lopinavir/ritonavir combination antiretroviral therapy. AIDS 25:5, 643-649
CrossRef71
B. J. Marais. (2011) Impact of Tuberculosis on Maternal and Child Health. Journal of Infectious Diseases 203:3, 304-305
CrossRef72
Stephen D Lawn, M Estée Török, Robin Wood. (2011) Optimum time to start antiretroviral therapy during HIV-associated opportunistic infections. Current Opinion in Infectious Diseases 24:1, 34-42
CrossRef73
G. U. van Zyl, W. Preiser, S. Potschka, A. T. Lundershausen, R. Haubrich, D. Smith. (2011) Pooling Strategies to Reduce the Cost of HIV-1 RNA Load Monitoring in a Resource-Limited Setting. Clinical Infectious Diseases 52:2, 264-270
CrossRef74
Laurence Ahoua, Gunar Guenther, Christine Rouzioux, Loretxu Pinoges, Paul Anguzu, Anne-Marie Taburet, Suna Balkan, David M Olson, Charles Olaro, Mar Pujades-Rodríguez. (2011) Immunovirological response to combined antiretroviral therapy and drug resistance patterns in children: 1- and 2-year outcomes in rural Uganda. BMC Pediatrics 11:1, 67
CrossRef75
Alberto N Ramos, Luiza H Matida, Norman Hearst, Jorg Heukelbach. (2011) Opportunistic illnesses in Brazilian children with AIDS: results from two national cohort studies, 1983-2007. AIDS Research and Therapy 8:1, 23
CrossRef76
Didier K Ekouevi, Alain Azondekon, Fatoumata Dicko, Karen Malateste, Pety Touré, François T Eboua, Kouakou Kouadio, Lorna Renner, Kevin Peterson, François Dabis, Haby Sy, Valeriane Leroy, . (2011) 12-month mortality and loss-to-program in antiretroviral-treated children: The IeDEA pediatric West African Database to evaluate AIDS (pWADA), 2000-2008. BMC Public Health 11:1, 519
CrossRef77
Quarraisha Karim, Anchilla Banegura, Pedro Cahn, Celia DC Christie, Robert Dintruff, Manuel Distel, Catherine Hankins, Nicholas Hellmann, Elly Katabira, Sandra Lehrman, Julio Montaner, Scott Purdon, James F Rooney, Robin Wood, Shirin Heidari. (2011) Asking the right questions: developing evidence-based strategies for treating HIV in women and children. BMC Public Health 11:1, 388
CrossRef78
M. Adhikari, P. Jeena, R. Bobat, M. Archary, K. Naidoo, A. Coutsoudis, R. Singh, N. Nair. (2011) HIV-Associated Tuberculosis in the Newborn and Young Infant. International Journal of Pediatrics 2011, 1-10
CrossRef79
Clotilde Hainline, Reghana Taliep, Gill Sorour, Sharon Nachman, Helena Rabie, Els Dobbels, Anita van Rensburg, Morna Cornell, Avy Violari, Shabir A Madhi, Mark F Cotton. (2011) Early Antiretroviral Therapy reduces the incidence of otorrhea in a randomized study of early and deferred antiretroviral therapy: Evidence from the Children with HIV Early Antiretroviral Therapy (CHER) Study. BMC Research Notes 4:1, 448
CrossRef80
Anirban Chatterjee, Sangeeta Tripathi, Robert Gass, Ndapewa Hamunime, Sok Panha, Charles Kiyaga, Abdoulaye Wade, Matthew Barnhart, Chewe Luo, Rene Ekpini. (2011) Implementing services for Early Infant Diagnosis (EID) of HIV: a comparative descriptive analysis of national programs in four countries. BMC Public Health 11:1, 553
CrossRef81
Andrea L Ciaranello, Ji-Eun Park, Lynn Ramirez-Avila, Kenneth A Freedberg, Rochelle P Walensky, Valeriane Leroy. (2011) Early infant HIV-1 diagnosis programs in resource-limited settings: opportunities for improved outcomes and more cost-effective interventions. BMC Medicine 9:1, 59
CrossRef82
Christiane Horwood, Lisa M. Butler, Kerry Vermaak, Nigel Rollins, Lyn Haskins, Phumla Nkosi, Torsten B. Neilands, Shamim Qazi. (2011) Disease profile of children under 5 years attending primary health care clinics in a high HIV prevalence setting in South Africa. Tropical Medicine & International Health 16:1, 42-52
CrossRef83
Christine J McGrath, Michael H Chung, Barbra A Richardson, Sarah Benki-Nugent, Danson Warui, Grace C John-Stewart. (2011) Younger age at HAART initiation is associated with more rapid growth reconstitution. AIDS 25:3, 345-355
CrossRef84
James J. C. Nuttall, Brian S. Eley. (2011) BCG Vaccination in HIV-Infected Children. Tuberculosis Research and Treatment 2011, 1-6
CrossRef85
Zikulah Namukwaya, Peter Mudiope, Adeodata Kekitiinwa, Philippa Musoke, Joyce Matovu, Sarah Kayma, William Salmond, Edward Bitarakwate, Michael Mubiru, Albert Maganda, Moses Galla, Josaphat Byamugisha, Mary Glenn Fowler. (2011) The Impact of Maternal Highly Active Antiretroviral Therapy and Short-Course Combination Antiretrovirals for Prevention of Mother-to-Child Transmission on Early Infant Infection Rates at the Mulago National Referral Hospital in Kampala, Uganda, January 2007 to May 2009. JAIDS Journal of Acquired Immune Deficiency Syndromes 56:1, 69-75
CrossRef86
Alemnesh H Mirkuzie, Sven Hinderaker, Mitike Sisay, Karen Moland, Odd Mørkve. (2011) Current status of medication adherence and infant follow up in the prevention of mother to child HIV transmission programme in Addis Ababa: a cohort study. Journal of the International AIDS Society 14:1, 50
CrossRef87
Avinash K. Shetty, Yvonne A. Maldonado. 2011. Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome in the Infant. , 622-660.
CrossRef88
S Ghosh, J Neubert, T Niehues, O Adams, N Morali-Karzei, A Borkhardt, HJ Laws. (2011) Induction maintenance concept for HAART as initial treatment in HIV infected infants. European Journal of Medical Research 16:6, 243
CrossRef89
Gwenn E. McLaughlin, Andrew C. Argent. 2011. Acquired Immune Dysfunction. , 1302-1314.
CrossRef90
Adriana Cadilla, Nadia Qureshi, Daniel C Johnson. (2010) Pediatric antiretroviral therapy. Expert Review of Anti-infective Therapy 8:12, 1381-1402
CrossRef91
Rawiwan Hansudewechakul, Virat Sirisanthana, Nia Kurniati, Thanyawee Puthanakit, Pagakrong Lumbiganon, Vonthanak Saphonn, Nik Khairulddin Nik Yusoff, Nagalingeswaran Kumarasamy, Siew Moy Fong, Revathy Nallusamy, Preeyaporn Srasuebkul, Matthew Law, Annette H Sohn, Kulkanya Chokephaibulkit. (2010) Antiretroviral Therapy Outcomes of HIV-Infected Children in the TREAT Asia Pediatric HIV Observational Database. JAIDS Journal of Acquired Immune Deficiency Syndromes 55:4, 503-509
CrossRef92
Andres F. Camacho-Gonzalez, Allison C. Ross, Rana Chakraborty. (2010) The Clinical Care of the HIV-1–Infected Infant. Clinics in Perinatology 37:4, 873-885
CrossRef93
Zaheer A Parpia, Robert Elghanian, Arman Nabatiyan, Diana R Hardie, David M Kelso. (2010) p24 Antigen Rapid Test for Diagnosis of Acute Pediatric HIV Infection. JAIDS Journal of Acquired Immune Deficiency Syndromes 55:4, 413-419
CrossRef94
Mary Glenn Fowler, Alicia R. Gable, Margaret A. Lampe, Monica Etima, Maxensia Owor. (2010) Perinatal HIV and Its Prevention: Progress Toward an HIV-free Generation. Clinics in Perinatology 37:4, 699-719
CrossRef95
Victor Mwapasa, Ada Cachafeiro, Yohane Makuta, David J. Beckstead, Michael L. Pennell, Ben Chilima, Beatrice Mwagomba, Susan A. Fiscus, Jesse J. Kwiek. (2010) Using a simplified human immunodeficiency virus type 1 p24 antigen assay to diagnose pediatric HIV-infection in Malawi. Journal of Clinical Virology 49:4, 299-302
CrossRef96
Mairi Thomson, Landon Myer, Heather J. Zar. (2010) The Impact of Pneumonia on Development of Chronic Respiratory Illness in Childhood. Pediatric Allergy, Immunology, and Pulmonology 23:4, 279-290
CrossRef97
Louise Kuhn, Grace Aldrovandi. (2010) Survival and Health Benefits of Breastfeeding Versus Artificial Feeding in Infants of HIV-Infected Women: Developing Versus Developed World. Clinics in Perinatology 37:4, 843-862
CrossRef98
Asgeir Johannessen. (2010) Dried blood spots in HIV monitoring: applications in resource-limited settings. Bioanalysis 2:11, 1893-1908
CrossRef99
Maria LS Cruz, Claudete A Cardoso, Esau C João, Ivete M Gomes, Thalita F Abreu, Ricardo H Oliveira, Elizabeth S Machado, Ilda R Dias, Norma M Rubini, Regina M Succi. (2010) Pregnancy in HIV vertically infected adolescents and young women: a new generation of HIV-exposed infants. AIDS 24:17, 2727-2731
CrossRef100
Robin Wood. (2010) When to start antiretroviral therapy in children with TB?. Expert Review of Anti-infective Therapy 8:10, 1101-1104
CrossRef101
D. Van der Linden, M. Cotton, H. Rabie, N. McKerrow. (2010) Fatal Hepatitis B Infection Despite Immunization in an HIV-infected Infant: A Possible Case of Vaccine Failure and Immune Reconstitution Inflammatory Syndrome. Journal of Tropical Pediatrics 56:5, 351-354
CrossRef102
Erik De Clercq. 2010. HIV Reverse Transcriptase Inhibitors. .
CrossRef103
Heather J Zar, Lesley Workman, Stanzi M le Roux, Teresa Jennings, Nomawethu Jele, Hendrick Simon Schaaf, Ann Barclay-Loggie, Chris Mulligan, David M le Roux, Carl J Lombard, Mark F Cotton. (2010) A randomized controlled trial of intermittent compared with daily cotrimoxazole preventive therapy in HIV-infected children. AIDS 24:14, 2225-2232
CrossRef104
A.D. Yeap, R. Hamilton, S. Charalambous, T. Dwadwa, G.J. Churchyard, P.W. Geissler, A.D. Grant. (2010) Factors influencing uptake of HIV care and treatment among children in South Africa – a qualitative study of caregivers and clinic staff. AIDS Care 22:9, 1101-1107
CrossRef105
Catherine G Sutcliffe, William J Moss. (2010) Do children infected with HIV receiving HAART need to be revaccinated?. The Lancet Infectious Diseases 10:9, 630-642
CrossRef106
Halina Frydman, Michael Szarek. (2010) Estimation of overall survival in an ‘illness-death’ model with application to the vertical transmission of HIV-1. Statistics in Medicine 29:19, 2045-2054
CrossRef107
Judy Orikiiriza, Sabrina Bakeera-Kitaka, Victor Musiime, Edison A Mworozi, Peter Mugyenyi, David R Boulware. (2010) The clinical pattern, prevalence, and factors associated with immune reconstitution inflammatory syndrome in Ugandan children. AIDS 24:13, 2009-2017
CrossRef108
A. Koppel, J. Leonardo-Guerrero, S. Rives, N. Paniagua-Torres, C. Sparrow, C. M. Beck-Sague. (2010) Immune Reconstitution Inflammatory Syndrome due to Mycobacterium bovis Bacillus Calmette-Guerin in Infants Receiving Highly Active Antiretroviral Therapy: A Call for Universal Perinatal Rapid HIV Testing Prior to Administration of BCG Immunization of Neonates. Journal of Tropical Pediatrics 56:4, 280-283
CrossRef109
, C. Giaquinto, M. Penazzato, R. Rosso, S. Bernardi, O. Rampon, P. Nasta, A. Ammassari, A. Antinori, R. Badolato, G. Castelli Gattinara, A. d’Arminio Monforte, M. De Martino, A. De Rossi, P. Di Gregorio, S. Esposito, F. Fatuzzo, S. Fiore, A. Franco, C. Gabiano, L. Galli, O. Genovese, V. Giacomet, A. Giannattasio, C. Gotta, A. Guarino, A. Martino, F. Mazzotta, N. Principi, M. B. Regazzi, P. Rossi, R. Russo, M. Saitta, F. Salvini, S. Trotta, A. Viganò, G. Zuccotti, G. Carosi. (2010) Italian consensus statement on paediatric HIV infection. Infection 38:4, 301-319
CrossRef110
Paula Braitstein, Adrian Katshcke, Changyu Shen, Edwin Sang, Winstone Nyandiko, Vincent Ooko Ochieng, Rachel Vreeman, Constantin T. Yiannoutsos, Kara Wools-Kaloustian, Samwel Ayaya. (2010) Retention of HIV-infected and HIV-exposed children in a comprehensive HIV clinical care programme in Western Kenya. Tropical Medicine & International Health 15:7, 833-841
CrossRef111
H. Simon SCHAAF, Andrea COLLINS, Adrie BEKKER, Peter D.O. DAVIES. (2010) Tuberculosis at extremes of age. Respirology 15:5, 747-763
CrossRef112
M-F Anaky, J Duvignac, L Wemin, A Kouakoussui, S Karcher, S Touré, C Seyler, P Fassinou, F Dabis, T N’Dri-Yoman, X Anglaret, V Leroy. (2010) Scaling up antiretroviral therapy for HIV-infected children in Côte d’Ivoire: determinants of survival and loss to programme. Bulletin of the World Health Organization 88:7, 490-499
CrossRef113
Cabot, Richard C.Harris, Nancy Lee, Shepard, Jo-Anne O., Rosenberg, Eric S., Cort, Alice M., Ebeling, Sally H.Peters, Christine C., Meyers, Tammy M., Ndung'u, Thumbi, . (2010) Case 18-2010. New England Journal of Medicine 362:24, 2305-2312
Full Text114
JOANNE POTTERTON, AIMEE STEWART, PETER COOPER, PIETER BECKER. (2010) The effect of a basic home stimulation programme on the development of young children infected with HIV. Developmental Medicine & Child Neurology 52:6, 547-551
CrossRef115
Rashida Ferrand, Sara Lowe, Barbra Whande, Lucia Munaiwa, Lisa Langhaug, Frances Cowan, Owen Mugurungi, Diana Gibb, Shungu Munyati, Brian G Williams, Elizabeth L Corbett. (2010) Survey of children accessing HIV services in a high prevalence setting: time for adolescents to count?. Bulletin of the World Health Organization 88:6, 428-434
CrossRef116
Ben J Marais, Mario C Raviglione, Peter R Donald, Anthony D Harries, Afranio L Kritski, Stephen M Graham, Wafaa M El-Sadr, Mark Harrington, Gavin Churchyard, Peter Mwaba, Ian Sanne, Stefan HE Kaufmann, Christopher JM Whitty, Rifat Atun, Alimuddin Zumla. (2010) Scale-up of services and research priorities for diagnosis, management, and control of tuberculosis: a call to action. The Lancet 375:9732, 2179-2191
CrossRef117
C. Horwood, L. Haskins, K. Vermaak, S. Phakathi, R. Subbaye, T. Doherty. (2010) Prevention of mother to child transmission of HIV (PMTCT) programme in KwaZulu-Natal, South Africa: an evaluation of PMTCT implementation and integration into routine maternal, child and women’s health services. Tropical Medicine & International Healthno-no
CrossRef118
Marcel Yotebieng, Annelies Van Rie, Harry Moultrie, Stephen R Cole, Adaora Adimora, Frieda Behets, Tammy Meyers. (2010) Effect on mortality and virological response of delaying antiretroviral therapy initiation in children receiving tuberculosis treatment. AIDS 24:9, 1341-1349
CrossRef119
Vivek Jain, Steven G. Deeks. (2010) When to Start Antiretroviral Therapy. Current HIV/AIDS Reports 7:2, 60-68
CrossRef120
R.R. Lilian, K. Bhowan, G.G. Sherman. (2010) Early diagnosis of human immunodeficiency virus-1 infection in infants with the NucliSens EasyQ assay on dried blood spots. Journal of Clinical Virology 48:1, 40-43
CrossRef121
Natascha Ching, Karin A. Nielsen-Saines, Jaime G. Deville, Lian S. Wei, Eileen Garratty, Yvonne J. Bryson. (2010) Autologous Neutralizing Antibody to Human Immunodeficiency Virus-1 and Replication-Competent Virus Recovered from CD4 + T-Cell Reservoirs in Pediatric HIV-1–Infected Patients on HAART. AIDS Research and Human Retroviruses 26:5, 585-591
CrossRef122
Anthony D Harries, Rony Zachariah, Elizabeth L Corbett, Stephen D Lawn, Ezio T Santos-Filho, Rhehab Chimzizi, Mark Harrington, Dermot Maher, Brian G Williams, Kevin M De Cock. (2010) The HIV-associated tuberculosis epidemic—when will we act?. The Lancet 375:9729, 1906-1919
CrossRef123
Ray Lazarus, Helen Struthers, Avy Violari. (2010) Starting HIV-positive Babies on Antiretroviral Treatment: Perspectives of Mothers in Soweto, South Africa. Journal of Pediatric Health Care 24:3, 176-183
CrossRef124
Penny M Enarson, Robert P Gie, Donald A Enarson, Charles Mwansambo, Stephen M Graham. (2010) Impact of HIV on standard case management for severe pneumonia in children. Expert Review of Respiratory Medicine 4:2, 211-220
CrossRef125
Gabriela Marón, Aditya H. Gaur, Patricia M. Flynn. (2010) Antiretroviral Therapy in HIV-Infected Infants and Children. The Pediatric Infectious Disease Journal 29:4, 360-363
CrossRef126
DM Gray, HJ Zar. (2010) Community-acquired pneumonia in HIV-infected children: a global perspective. Current Opinion in Pulmonary Medicine1
CrossRef127
K Peltzer, G Mlambo. (2010) Factors determining HIV viral testing of infants in the context of mother-to-child transmission. Acta Paediatrica 99:4, 590-596
CrossRef128
Christiane Horwood. (2010) Prevention of mother-to-child HIV transmission in South Africa: the dawning of a new era. HIV Therapy 4:2, 127-130
CrossRef129
Rohan Hazra, George K. Siberry, Lynne M. Mofenson. (2010) Growing Up with HIV: Children, Adolescents, and Young Adults with Perinatally Acquired HIV Infection*. Annual Review of Medicine 61:1, 169-185
CrossRef130
James Ndirangu, Marie-Louise Newell, Frank Tanser, Abraham J Herbst, Ruth Bland. (2010) Decline in early life mortality in a high HIV prevalence rural area of South Africa: evidence of HIV prevention or treatment impact?. AIDS 24:4, 593-602
CrossRef131
Punam Mangtani, Kim Mulholland, Shabir A. Madhi, Karen Edmond, Rosalyn O’Loughlin, Rana Hajjeh. (2010) Haemophilus influenzae type b disease in HIV-infected children: A review of the disease epidemiology and effectiveness of Hib conjugate vaccines. Vaccine 28:7, 1677-1683
CrossRef132
Caroline Mitchell, Kelli Kraft, Do Peterson, Lisa Frenkel. (2010) Cross-contamination during processing of dried blood spots used for rapid diagnosis of HIV-1 infection of infants is rare and avoidable. Journal of Virological Methods 163:2, 489-491
CrossRef133
Agnes Nalwoga, Dermot Maher, Jim Todd, Alex Karabarinde, Samuel Biraro, Heiner Grosskurth. (2010) Nutritional status of children living in a community with high HIV prevalence in rural Uganda: a cross-sectional population-based survey. Tropical Medicine & International Health
CrossRef134
Martina Penazzato, Daniele Donà, Pia-Sophie Wool, Osvalda Rampon, Carlo Giaquinto. (2010) Update on antiretroviral therapy in paediatrics. Antiviral Research 85:1, 266-275
CrossRef135
Camille Lallemant, Gaston Halembokaka, Gaelle Baty, Nicole Ngo-Giang-Huong, Francis Barin, Sophie Le Coeur. (2010) Impact of HIV/Aids on Child Mortality before the Highly Active Antiretroviral Therapy Era: A Study in Pointe-Noire, Republic of Congo. Journal of Tropical Medicine 2010, 1-6
CrossRef136
Annette H Sohn, James JC Nuttall, Fuije Zhang. (2010) Sequencing of antiretroviral therapy in children in low- and middle-income countries. Current Opinion in HIV and AIDS 5:1, 54-60
CrossRef137
M Chopra, T Doherty, A Goga, D Jackson, LA Persson. (2010) Survival of infants in the context of prevention of mother to child HIV transmission in South Africa. Acta Paediatrica
CrossRef138
Michael T Brady, James M Oleske, Paige L Williams, Carol Elgie, Lynne M Mofenson, Wayne M Dankner, Russell B Van Dyke. (2010) Declines in Mortality Rates and Changes in Causes of Death in HIV-1-Infected Children During the HAART Era. JAIDS Journal of Acquired Immune Deficiency Syndromes 53:1, 86-94
CrossRef139
Jessica Lidström, Qing Li, Donald R Hoover, George Kafulafula, Lynne M Mofenson, Mary G Fowler, Michael C Thigpen, Newton Kumwenda, Taha E Taha, Susan H Eshleman. (2010) Addition of extended zidovudine to extended nevirapine prophylaxis reduces nevirapine resistance in infants who were HIV-infected in utero. AIDS 24:3, 381-386
CrossRef140
Joseph Tucker, Xin Ren, Flora Sapio. (2010) Incarcerated sex workers and HIV prevention in China: Social suffering and social justice countermeasures. Social Science & Medicine 70:1, 121-129
CrossRef141
Christiane Horwood, Anna Voce, Kerry Vermaak, Nigel Rollins, Shamim Qazi. (2010) Routine checks for HIV in children attending primary health care facilities in South Africa: Attitudes of nurses and child caregivers. Social Science & Medicine 70:2, 313-320
CrossRef142
Thanyawee Puthanakit, Torsak Bunupuradah. (2010) Early versus deferred antiretroviral therapy in children in low-income and middle-income countries. Current Opinion in HIV and AIDS 5:1, 12-17
CrossRef143
Wilson L. Mandala, Jenny M. MacLennan, Esther N. Gondwe, Steven A. Ward, Malcolm E. Molyneux, Calman A. MacLennan. (2010) Lymphocyte subsets in healthy Malawians: Implications for immunologic assessment of HIV infection in Africa. Journal of Allergy and Clinical Immunology 125:1, 203-208
CrossRef144
Brenda M. Morrow, Nei-Yuan Hsaio, Marco Zampoli, Andrew Whitelaw, Heather J. Zar. (2010) Pneumocystis Pneumonia in South African Children With and Without Human Immunodeficiency Virus Infection in the Era of Highly Active Antiretroviral Therapy. The Pediatric Infectious Disease Journal1
CrossRef145
Annelies Van Rie, Anna Dow, Aimee Mupuala, Paul Stewart. (2009) Neurodevelopmental Trajectory of HIV-Infected Children Accessing Care in Kinshasa, Democratic Republic of Congo. JAIDS Journal of Acquired Immune Deficiency Syndromes 52:5, 636-642
CrossRef146
Ben J. Marais, Helen Ayles, Stephen M. Graham, Peter Godfrey-Faussett. (2009) Screening and Preventive Therapy for Tuberculosis. Clinics in Chest Medicine 30:4, 827-846
CrossRef147
Carole L. Wallis, Linda Erasmus, Sheba Varughese, Dalu Ndiweni, Wendy S. Stevens. (2009) EMERGENCE OF DRUG RESISTANCE IN HIV-1 SUBTYPE C INFECTED CHILDREN FAILING THE SOUTH AFRICAN NATIONAL ANTIRETROVIRAL ROLL-OUT PROGRAM. The Pediatric Infectious Disease Journal 28:12, 1123-1125
CrossRef148
A. Johannessen, M. Troseid, A. Calmy. (2009) Dried blood spots can expand access to virological monitoring of HIV treatment in resource-limited settings. Journal of Antimicrobial Chemotherapy 64:6, 1126-1129
CrossRef149
A. Boulle, B. Eley. (2009) Commentary: Reducing HIV-associated tuberculosis in children. International Journal of Epidemiology 38:6, 1621-1623
CrossRef150
Philippa M Musoke, Linda Barlow-Mosha, Danstan Bagenda, Peter Mudiope, Michael Mubiru, Patrick Ajuna, James K Tumwine, Mary Glenn Fowler. (2009) Response to Antiretroviral Therapy in HIV-Infected Ugandan Children Exposed and Not Exposed to Single-Dose Nevirapine at Birth. JAIDS Journal of Acquired Immune Deficiency Syndromes 52:5, 560-568
CrossRef151
Gert U. van Zyl, Lize van der Merwe, Mathilda Claassen, Mark F. Cotton, Helena Rabie, Hans W. Prozesky, Wolfgang Preiser. (2009) PROTEASE INHIBITOR RESISTANCE IN SOUTH AFRICAN CHILDREN WITH VIROLOGIC FAILURE. The Pediatric Infectious Disease Journal 28:12, 1125-1127
CrossRef152
Gert U. van Zyl, Mark F. Cotton, Mathilda Claassen, Charmaine Abrahams, Wolfgang Preiser. (2009) SURVEILLANCE OF TRANSMITTED RESISTANCE TO ANTIRETROVIRAL DRUG CLASSES AMONG YOUNG CHILDREN IN THE WESTERN CAPE PROVINCE OF SOUTH AFRICA. The Pediatric Infectious Disease Journal1
CrossRef153
JoAnna K. Leyenaar, Paul M. Novosad, Katheleen T. Ferrer, Lineo K. Thahane, Edith Q. Mohapi, Gordon E. Schutze, Mark W. Kline. (2009) Early Clinical Outcomes in Children Enrolled in Human Immunodeficiency Virus Infection Care and Treatment in Lesotho. The Pediatric Infectious Disease Journal1
CrossRef154
James EG Bunn. (2009) Severe acute malnutrition and HIV in African children. HIV Therapy 3:6, 595-611
CrossRef155
Cécile Alexandra Peltier, Gilles François Ndayisaba, Philippe Lepage, Johan van Griensven, Valériane Leroy, Christine Omes Pharm, Patrick Cyaga Ndimubanzi, Olivier Courteille, Vic Arendt. (2009) Breastfeeding with maternal antiretroviral therapy or formula feeding to prevent HIV postnatal mother-to-child transmission in Rwanda. AIDS 23:18, 2415-2423
CrossRef156
Mwangelwa Mubiana-Mbewe, Carolyn Bolton-Moore, Yolan Banda, Namwinga Chintu, Mutinta Nalubamba-Phiri, Mark Giganti, M. Brad Guffey, Pauline Sambo, Elizabeth M. Stringer, Jeffrey S. A. Stringer, Benjamin H. Chi. (2009) Causes of morbidity among HIV-infected children on antiretroviral therapy in primary care facilities in Lusaka, Zambia. Tropical Medicine & International Health 14:10, 1190-1198
CrossRef157
Pamela Fergusson, Andrew Tomkins, Marko Kerac. (2009) Improving survival of children with severe acute malnutrition in HIV-prevalent settings. International Health 1:1, 10-16
CrossRef158
Nigel Rollins, Similo Mzolo, Tammy Moodley, Tonya Esterhuizen, Heidi van Rooyen. (2009) Universal HIV testing of infants at immunization clinics: an acceptable and feasible approach for early infant diagnosis in high HIV prevalence settings. AIDS 23:14, 1851-1857
CrossRef159
Kunjal Patel, Xue Ming, Paige L Williams, Kevin R Robertson, James M Oleske, George R Seage. (2009) Impact of HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy among perinatally infected children and adolescents. AIDS 23:14, 1893-1901
CrossRef160
Sarah M Wood, Samir S Shah, Andrew P Steenhoff, Richard M Rutstein. (2009) The impact of AIDS diagnoses on long-term neurocognitive and psychiatric outcomes of surviving adolescents with perinatally acquired HIV. AIDS 23:14, 1859-1865
CrossRef161
Annette H Sohn, Jintanat Ananworanich. (2009) HAART for children with treatment failure. HIV Therapy 3:5, 485-499
CrossRef162
Bradley C. Fetzer, Mina C. Hosseinipour, Portia Kamthuzi, Lisa Hyde, Brian Bramson, Kebba Jobarteh, Kristine Torjesen, William C. Miller, Irving Hoffman, Peter Kazembe, Charles Mwansambo. (2009) Predictors for mortality and loss to follow-up among children receiving anti-retroviral therapy in Lilongwe, Malawi. Tropical Medicine & International Health 14:8, 862-869
CrossRef163
Ben J Marais, H Simon Schaaf, Peter R Donald. (2009) Pediatric TB: issues related to current and future treatment options. Future Microbiology 4:6, 661-675
CrossRef164
Dolly Sharma, Rana Chakraborty. (2009) Managing HIV infection in infants, children and adolescents with HAART. HIV Therapy 3:4, 391-404
CrossRef165
Jessica D. Church, Anthony Mwatha, Danstan Bagenda, Saad B. Omer, Deborah Donnell, Philippa Musoke, Clemensia Nakabiito, Chineta Eure, Paul Bakaki, Flavia Matovu, Michael C. Thigpen, Laura A. Guay, Michelle McConnell, Mary Glenn Fowler, J. Brooks Jackson, Susan H. Eshleman. (2009) In Utero HIV Infection Is Associated with an Increased Risk of Nevirapine Resistance in Ugandan Infants Who Were Exposed to Perinatal Single Dose Nevirapine. AIDS Research and Human Retroviruses 25:7, 673-677
CrossRef166
Chipepo Kankasa, Rosalind J Carter, Nancy Briggs, Marc Bulterys, Eslone Chama, Ellen R Cooper, Cristiane Costa, Erica Spielman, Mary Katepa-Bwalya, Tendai Mʼsoka, Katai Chola, Chin-Yih Ou, Elaine J Abrams. (2009) Routine Offering of HIV Testing to Hospitalized Pediatric Patients at University Teaching Hospital, Lusaka, Zambia: Acceptability and Feasibility. JAIDS Journal of Acquired Immune Deficiency Syndromes 51:2, 202-208
CrossRef167
Ravindra K Gupta, Diana M Gibb, Deenan Pillay. (2009) Management of paediatric HIV-1 resistance. Current Opinion in Infectious Diseases 22:3, 256-263
CrossRef168
Kelly Smith, Louise Kuhn, Ashraf Coovadia, Tammy Meyers, Chih-Chi Hu, Cordula Reitz, Gillian Barry, Renate Strehlau, Gayle Sherman, Elaine J Abrams. (2009) Immune reconstitution inflammatory syndrome among HIV-infected South African infants initiating antiretroviral therapy. AIDS 23:9, 1097-1107
CrossRef169
S. Pensieroso, A. Cagigi, P. Palma, A. Nilsson, C. Capponi, E. Freda, S. Bernardi, R. Thorstensson, F. Chiodi, P. Rossi. (2009) From the Cover: Timing of HAART defines the integrity of memory B cells and the longevity of humoral responses in HIV-1 vertically-infected children. Proceedings of the National Academy of Sciences 106:19, 7939-7944
CrossRef170
Christy A Beneri, Sharon Nachman. (2009) To treat or not to treat? No longer a question. Future Microbiology 4:4, 391-395
CrossRef171
Freddy Perez, Valériane Leroy. (2009) Pediatric adherence to antiretroviral therapy in resource-poor settings: challenges and future perspectives. HIV Therapy 3:3, 213-219
CrossRef172
Charlotte V Hobbs, Shaffiq M Essajee. (2009) Early treatment of HIV: implications for resource-limited settings. Current Opinion in HIV and AIDS1
CrossRef173
Bénédicte Brichard, Dimitri Linden. (2009) Clinical practice treatment of HIV infection in children. European Journal of Pediatrics 168:4, 387-392
CrossRef174
Hendramoorthy Maheswaran, Ruth M Bland. (2009) Preventing mother-to-child transmission of HIV in resource-limited settings. Future Virology 4:2, 165-175
CrossRef175
Tessa Goetghebuer, Edwige Haelterman, Jerome Le Chenadec, Catherine Dollfus, Diana Gibb, Ali Judd, Hannah Green, Luisa Galli, Jose Tomas Ramos, Carlo Giaquinto, Josiane Warszawski, Jack Levy. (2009) Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants. AIDS 23:5, 597-604
CrossRef176
Caroline Foster, Ali Judd, Pat Tookey, Gareth Tudor-Williams, David Dunn, Delane Shingadia, Karina Butler, Mike Sharland, Di Gibb, Hermione Lyall. (2009) Young People in the United Kingdom and Ireland with Perinatally Acquired HIV: The Pediatric Legacy For Adult Services. AIDS Patient Care and STDs 23:3, 159-166
CrossRef177
Ellen Gould Chadwick, Jorge Pinto, Ram Yogev, Carmelita G. Alvero, Michael D. Hughes, Paul Palumbo, Brian Robbins, Rohan Hazra, Leslie Serchuck, Barbara E. Heckman, Lynette Purdue, Renee Browning, Katherine Luzuriaga, John Rodman, Edmund Capparelli. (2009) Early Initiation of Lopinavir/Ritonavir in Infants Less Than 6 Weeks of Age. The Pediatric Infectious Disease Journal 28:3, 215-219
CrossRef178
Jacyntha A. Sterling. (2009) Hospital Pharmacy Pulse - Recent Publications on Medications and Pharmacy. Hospital Pharmacy 44:2, 193-199
CrossRef179
M. H. Rathore. (2009) Diagnosis and Therapy of HIV-Infected Infants: Earlier Is Better. AAP Grand Rounds 21:2, 18-18
CrossRef180
David E Bourne, MaryLou Thompson, Linnea L Brody, Mark Cotton, Beverly Draper, Ria Laubscher, M Fareed Abdullah, Jonny E Myers. (2009) Emergence of a peak in early infant mortality due to HIV/AIDS in South Africa. AIDS 23:1, 101-106
CrossRef181
Filip Josephson, Jan Albert, Leo Flamholc, Magnus Gisslén, Olof Karlström, Lars Moberg, Lars Navér, Veronica Svedhem, Bo Svennerholm, Anders Sönnerborg. (2009) Treatment of HIV infection: Swedish recommendations 2009. Scandinavian Journal of Infectious Diseases 41:11-12, 788-807
CrossRef
